Gabapentin reduces hot flashes
A 900-mg daily dose of gabapentin reduces hot flashes in women with natural menopause. So said Canadian investigators reporting on results of a new randomized clinical trial at the 17th annual meeting of the North American Menopause Society in Nashville, Tenn.
A 900-mg daily dose of gabapentin reduces hot flashes in women with natural menopause. So said Canadian investigators reporting on results of a new randomized clinical trial at the 17th annual meeting of the North American Menopause Society in Nashville, Tenn.
More than 200 women aged 45 to 66 who had undergone natural menopause were enrolled in the trial. All were experiencing 14 or more hot flashes per week and were randomized to 300 mg of oral gabapentin TID or placebo for 4 weeks.
Daily hot flash diaries kept by the women beginning a week before the trial showed a twofold improvement in symptoms among those on gabapentin compared with placebo (P=0.0007). Hot flash scores dropped by 52% (95% CI; 43–65) in the treatment group versus 27% (95% CI; 15–41) in the sham group.
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More
